DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/t9b48b/chronic_pain) has announced the addition of the "Chronic Pain - Pipeline Review, H1 2015" report to their offering.
This report provides comprehensive information on the therapeutic development for Chronic Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Pain and special features on late-stage and discontinued projects.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Companies Involved in Therapeutics Development
- AbbVie Inc.
- Acadia Pharmaceuticals Inc.
- Adynxx, Inc.
- Akron Molecules AG
- Allergan, Inc.
- arGEN-X BV
- Astellas Pharma Inc.
- Astraea Therapeutics, LLC
- AstraZeneca PLC
- BCN Peptides, S.A.
- BioDelivery Sciences International, Inc.
- Bionomics Limited
- Cara Therapeutics, Inc.
- ChironWells GmbH
- Chromocell Corporation
- Collegium Pharmaceutical, Inc.
- CoLucid Pharmaceuticals, Inc.
- Convergence Pharmaceuticals Ltd.
- Creabilis SA
- Cytogel Pharma, LLC
- Daewoong Pharmaceutical Co., Ltd.
- Daiichi Sankyo Company, Limited
- Dompe Farmaceutici S.p.A.
- DURECT Corporation
- Egalet Corporation
- Eli Lilly and Company
- Endo Pharmaceuticals Inc.
- Glenmark Pharmaceuticals Ltd.
- Grunenthal GmbH
- Johnson & Johnson
For more information visit http://www.researchandmarkets.com/research/t9b48b/chronic_pain